Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-09-13
2005-09-13
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S547000
Reexamination Certificate
active
06943156
ABSTRACT:
The present invention relates to a novel dibenzoxazepine derivative, its synthesis, and its use as an αv integrin receptor antagonist. More particularly, the compound of the present invention is an antagonist of the integrin receptors αvβ3 and αvβ5 and therefor useful for inhibiting bone resorption, treating and/or preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, artheroscietosis, inflammatory arthritis, cancer and metastatic tumor growth.
REFERENCES:
patent: 6069158 (2000-05-01), Miller et al.
Hartman et al., Alpha.sub.vbeta.sub.3 Integrin Antagonists as Inhibitors of Bone Resorption, Expert Opinion on Investigational Drugs, Jun. 2000, vol. 9, No. 6, pp. 1281-1291.
Miller et al., Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic, Journal of Medicinal Chemistry, Jan. 13, 2000, vol. 43, No. 1, pp. 22-26.
Coleman Brenda
Daniel Mark R.
Merck & Co. Inc
Shatynski Patricia A.
LandOfFree
Dibenzoxazepine αv integrin receptor antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dibenzoxazepine αv integrin receptor antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dibenzoxazepine αv integrin receptor antagonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3413950